Galectin Therapeutics Inc. (GALT) was among the biggest gainers on the Russell 2000 for Wednesday February 17 as the stock popped 5.45% to $1.16, representing a gain of $0.06 per share. Some 157,627 shares traded hands on 618 trades, compared with an average daily volume of 126,977 shares out of a total float of 23.93 million. The stock opened at $1.10 and traded with an intraday range of $1.17 to $1.10.
After today's gains, Galectin Therapeutics Inc. reached a market cap of $27.76 million. Galectin Therapeutics Inc. has had a trading range between $4.40 and $1.08 over the last year, and it had a 50-day SMA of $1.51 and a 200-day SMA of $2.30.
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
Galectin Therapeutics Inc. is based out of Norcross, GA and has some 7 employees. Its CEO is .
For a complete fundamental analysis analysis of Galectin Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for GALT. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.